Skip to content
DataLookout
Menu

OCEANNCT05263934

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 22 versions: 20 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 24 words Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Trial completed
    • Study sites: 63 to 65
    • Primary completion date changed from estimate of Sep 29, 2026 to Oct 6, 2026
    • Secondary endpoints: details revised at 8 of 9 entries
  2. Minor Study sites: 76 to 63v20
  3. Notable Eligibility criteria expanded, about 6 words
    • Secondary endpoints revised (9)
    • Site details revised at 32 of 76 sites
    v19
  4. Minor Trial status: Recruiting to Active, Not Recruitingv18 Show 4 more changesShow less
    • Enrollment target: estimated 160 to confirmed 163
    • Study sites: 81 to 76
    • Primary completion date: Oct 27, 2026 to Sep 29, 2026
    • Study completion date: Nov 24, 2026 to Oct 27, 2026
  5. Minor Study sites: 83 to 81v17
Show 14 earlier versionsHide 14 earlier versions
  1. Minor Primary completion date: May 27, 2026 to Oct 27, 2026
    • Study completion date: Jun 24, 2026 to Nov 24, 2026
    • Site details revised at 7 of 83 sites
    v16
  2. Minor Study sites: 82 to 83v15
  3. Minor Primary completion date: Mar 27, 2026 to May 27, 2026
    • Study completion date: Apr 24, 2026 to Jun 24, 2026
    v14
  4. Minor Study sites: 88 to 82
    • Primary completion date: Oct 10, 2025 to Mar 27, 2026
    • Study completion date: Nov 7, 2025 to Apr 24, 2026
    v13
  5. Minor Study sites: 86 to 88v12
  6. Minor Study sites: 85 to 86v11
  7. Minor Study sites: 33 to 85v10
  8. Minor Study sites: 21 to 33v8
  9. Minor Study sites: 20 to 21v7
  10. Notable Eligibility criteria expanded, about 42 words
    • Study sites: 19 to 20
    v6
  11. Minor Study sites: 8 to 19v5
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 2 to 8
    • Start date changed from estimate of Jul 29, 2022 to Jul 14, 2022
    v4
  13. Notable Start date: Jun 10, 2022 to Jul 29, 2022
    • Study sites: 1 to 2
    v3
  14. Notable Start date: Mar 14, 2022 to Jun 10, 2022
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with remission (Birmingham Vasculitis Activity Score [BVAS] =0 and a dose of oral corticosteroid [OCS] less than or equal to [<=] 4 milligram [mg] per day)
Timeframe: Up to Week 52

Secondary (9)

Number of participants in each category of accrued duration of remission
Number of participants with total accrued duration of remission
Time to first EGPA relapse
Number of participants receiving in each category of mean OCS dose during the last 4 weeks of study treatment period (Weeks 49 to 52)
Number of participants achieving remission (BVAS = 0 and OCS <= 4 mg/day) within the first 24 weeks with continued remission until Week 52
Show 4 moreShow less
Number of participants achieving remission using the European League against Rheumatism (EULAR) definition (BVAS = 0 and OCS <=7.5 mg/day) at Weeks 36 and 52
Number of participants in each category of accrued duration of remission according to the EULAR definition of remission (BVAS = 0 plus OCS <=7.5 mg/day) over 52-week intervention period
Number of participants with total accrued duration of remission according to the EULAR definition of remission
Number of participants with remission (BVAS=0 and OCS <=7.5 mg/day) within the first 24 weeks with continued remission until Week 52

Arms and interventions

Participants receiving depemokimab+placebo matching mepolizumabExperimental
Participants receiving mepolizumab+placebo matching depemokimabActive comparator

Biologicals: Depemokimab, Mepolizumab

Drugs: Placebo matching mepolizumab, Placebo matching depemokimab

Sites

65 sites in 19 countries

Italy 10, China 8, United States 6, Japan 5, South Korea 5, Spain 5, France 4, Poland 3, United Kingdom 3, Argentina 2, Brazil 2, Canada 2, Germany 2, Netherlands 2, Portugal 2, Austria 1, Hungary 1, Israel 1, Sweden 1